PHIO Phio Pharmaceuticals Corp.

NASDAQ
$0.80

Phio Pharmaceuticals Corp. (PHIO) is confirmed to report earnings on November 5, 2026, after the market close. The consensus earnings estimate is a loss of $0.36 per share.

Phio Pharmaceuticals Reported In-line with Estimates
Thursday, November 5, 2026 · 4:05 PM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 5
Thursday · After Close
Earnings Whisper
-
vs ($0.36)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $1.05

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Phio Pharmaceuticals Corp.

Phio Pharmaceuticals Corp is focused on developing immuno-oncology therapeutics based on its proprietary self-delivering RNAi therapeutic platform. The Company's pipeline consists of RXI-762 and RXI-804 which are in clinical stage. Phio Pharmaceuticals Corp, formerly known as RXi Pharmaceuticals Corporation, is based in Marlborough, United States.

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.